DAVIS STEPHEN 4
4 · ACADIA PHARMACEUTICALS INC · Filed Feb 27, 2024
Insider Transaction Report
Form 4
DAVIS STEPHEN
EVP, CFO AND CBO
Transactions
- Sale
Common Stock
2024-02-26$24.67/sh−5,577$137,585→ 101,890 total - Exercise/Conversion
Restricted Stock Units
2024-02-23−10,946→ 10,946 total→ Common Stock (10,946 underlying) - Exercise/Conversion
Common Stock
2024-02-23+10,946→ 107,467 total
Footnotes (3)
- [F1]Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- [F2]The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
- [F3]The restricted stock units vest in four equal annual installments beginning February 23, 2022.